paclitaxel,sotigalimab,nivolumab
bms
['prince', 'pcsm']
 happening now:
distinct biosignatures associate with survival after 1l chemo-io in patients with #mpdac #pcsm #princetrial immuno-pharmacodynamic effect. #asco22 #asco22cm 
@UconnIM | HemOnc @AUBMC_Official | @USEKofficial Alumni | @ASCO SM Editor @JCOGO_ASCO | VTP Award @ASH_Hematology | Views are my own FCOI: https://t.co/nLxBFc8CcY